Access Scientific, a provider of over-wire vascular access technology, has announced it has completed an acquisition agreement with Endeavour Capital.
Access Scientific manufactures the Powerwand extended dwell, power-injectable midline IV catheter inserted by means of the Wand’s proprietary Accelerated Seldinger Technique. The device is FDA cleared for the administration of fluids/medications and for the withdrawal of blood for diagnostic testing and can be left in place for up to 29 days.
“We are very pleased with the traction Powerwand has seen in the marketplace. The technology has the potential to significantly improve the patient’s hospital experience by requiring a single needlestick for vascular access throughout the length of stay. Endeavour’s investment will allow us to increase our efforts to bring this groundbreaking vascular access technology to the marketplace,” said Steve Bierman, CEO of Access Scientific.
“Access Scientific’s products provide clinical differentiation within the vascular access market. We believe the technology is impactful to both clinicians and patients, and we are excited to provide the growth capital necessary to support Access Scientific’s growth and success,” said Mark Dorman, managing director, Endeavour Capital.